|
Wyeth Pharmaceuticals |
|
|
Acquisition |
USD 68,000,000,000 |
|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM)
|
Acelrx Pharmaceuticals Inc |
|
Specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. |
Debt |
|
|
|
|
Imclone Systems |
|
|
Acquisition |
USD 7,133,620,000 |
|
|
ZocDoc Inc |
|
Provider of physician finder and appointment booking services. |
Series A |
|
|
|
|
Achillion Pharmaceuticals Inc |
|
Biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. |
N/A |
|
|
|
|
Zonare Medical Systems Inc |
|
|
Venture |
|
|
|
|
Millennium Pharmaceuticals Inc |
|
|
Acquisition |
USD 8,689,310,000 |
|
|
|
Bausch + Lomb Inc |
|
One of the best-known health-care brands in the world and offers one of the most comprehensive product portfolios in the ophthalmic industry. |
N/A |
|
|
|
|
Direct Flow Medical Inc |
|
Medical device developer |
Series B |
|
|
|
|
Zonare Medical Systems Inc |
|
|
Series E |
|
|
|
|
Visiogen Inc |
|
A medical device company focused on dual-optic accommodating intraocular lens, called Synchrony, for the treatment of age-related vision loss. |
N/A |
USD 24,000,000 |
|
|
|
NeoVista Inc |
|
|
Series C |
|
|
|
|
Elixir Pharmaceuticals Inc |
|
|
Series C |
|
|
|
|
NeoVista Inc |
|
|
Series B |
|
|
|
|
Ziopharm Oncology Inc |
|
Biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs. |
N/A |
|
|
|
|
Renal Care Group |
|
|
Acquisition |
USD 3,500,000,000 |
|
|
|
Direct Flow Medical Inc |
|
Medical device developer |
N/A |
|
|
|
ZyStor Therapeutics Inc |
|
|
Series A |
USD 8,500,000 |
|
|
|
Visiogen Inc |
|
A medical device company focused on dual-optic accommodating intraocular lens, called Synchrony, for the treatment of age-related vision loss. |
Venture |
USD 16,500,000 |
|
|
|
Visiogen Inc |
|
A medical device company focused on dual-optic accommodating intraocular lens, called Synchrony, for the treatment of age-related vision loss. |
Series B |
USD 5,000,000 |
|